Shuttle Pharmaceuticals Holdings (SHPH) Income from Continuing Operations (2021 - 2026)
Shuttle Pharmaceuticals Holdings (SHPH) recorded quarterly Income from Continuing Operations of 2228735.0 in Q1 2026, up 19.03% quarter-over-quarter from 2752595.0 in Q4 2025, and up 24.62% on a YoY basis from 1788435.87 in Q1 2025.
Shuttle Pharmaceuticals Holdings (SHPH) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Shuttle Pharmaceuticals Holdings' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 2228735.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 24.62% year-over-year to 2228735.0; the TTM figure through Mar 2026 stood at 11161446.0 (down 31.4% YoY), while the FY2025 annual figure was 11924464.0, down 55.54% from the prior year.
- Income from Continuing Operations was 2228735.0 for Q1 2026 at Shuttle Pharmaceuticals Holdings, up from 2752595.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 524017.0 in Q2 2022 to a low of 3912939.0 in Q2 2025.
- Historically, Income from Continuing Operations has averaged 1941516.65 across 5 years, with a median of 1899161.0 in 2024.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations slumped 492.21% in 2022, then surged 64.21% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 2718530.0 in 2022, then jumped by 39.65% to 1640500.0 in 2023, then soared by 64.21% to 587079.0 in 2024, then tumbled by 368.86% to 2752595.0 in 2025, then advanced by 19.03% to 2228735.0 in 2026.
- The last three Income from Continuing Operations figures came in at 2228735.0 (Q1 2026), 2752595.0 (Q4 2025), and 2267177.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Shuttle Pharmaceuticals Holdings | 2.17 Mn | 1.11 Mn | - | -2.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.23 Mn |
| Dec 31, 2025 | -2.75 Mn |
| Sep 30, 2025 | -2.27 Mn |
| Jun 30, 2025 | -3.91 Mn |
| Mar 31, 2025 | -2.96 Mn |
| Dec 31, 2024 | -587,079.00 |
| Sep 30, 2024 | -3.05 Mn |
| Jun 30, 2024 | -1.90 Mn |
| Mar 31, 2024 | -1.86 Mn |
| Dec 31, 2023 | -1.64 Mn |
| Sep 30, 2023 | -1.78 Mn |
| Jun 30, 2023 | -2.18 Mn |
| Mar 31, 2023 | -975,097.00 |
| Dec 31, 2022 | -2.72 Mn |
| Sep 30, 2022 | -998,425.00 |
| Jun 30, 2022 | -524,017.00 |
| Mar 31, 2022 | -681,839.00 |
| Dec 31, 2021 | -459,048.00 |
| Sep 30, 2021 | -216,961.00 |